FilingReader Intelligence
Hengrui Medicine seals $500m licensing deal with GSK
July 28, 2025 at 12:19 AM UTC•By FilingReader AI
Hengrui Medicine will license global exclusive rights for HRS-9821, a PDE3/4 inhibitor for COPD, and exclusive options for up to 11 additional projects to GSK, excluding Greater China.
GSK will pay $500 million upfront, with potential future payments from milestones reaching $12 billion, plus tiered sales royalties for Hengrui.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Jiangsu Hengrui Medicine publishes news
Free account required • Unsubscribe anytime